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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.04.014Objective: Left ventricular assist device (LVAD) insertion after anterior wall myo-
cardial infarction complicated by cardiogenic shock is an accepted modality of
support in select patients. Results of primary revascularization for these patients are
poor. We seek to determine the outcomes of patients with myocardial infarction and
shock who undergo LVAD insertion alone versus surgical revascularization before
LVAD insertion.
Methods: Seventy-four patients at 2 institutions underwent LVAD implantation for
myocardial infarction and shock over a 12-year period. Twenty-eight underwent
direct LVAD placement, and 46 underwent revascularization through coronary
artery bypass grafting before LVAD placement. Variables examined included pa-
tient demographics, myocardial infarction–LVAD interval, bridge to transplanta-
tion, early mortality (30 days), survival after LVAD placement, and posttrans-
plantation survivals.
Results: There were no differences in demographics between the 2 groups. The
group undergoing revascularization before LVAD placement had a lower bridge to
transplantation, higher early mortality, and lower overall 6- and 12-month survivals
after LVAD placement compared with the group undergoing direct LVAD place-
ment (45.50% vs 70.40%, P  .041; 39.10% vs 14.30%, P  .020; 89.3% and
82.1% vs 54.4% and 52.2%, respectively, P  .006). Posttransplantation survival
and LVAD explantation rates were equivalent in both groups.
Conclusions: Coronary artery bypass grafting before LVAD insertion for cardio-
genic shock complicating myocardial infarction adversely affects survival. Confir-
mation of these findings would require conducting a large, multicenter, randomized
clinical trial comparing revascularization versus LVAD support as primary therapy
in this setting.
Cardiogenic shock (CS) complicates 5% to 10% of cases of acute myocardialinfarction (MI) and has a mortality rate of up to 80% by 1 year.1 Percuta-neous coronary intervention (PCI; transluminal coronary angioplasty–stent
placement) and coronary artery bypass graft (CABG) surgery represent strategies to
revascularize the ischemic myocardium subserved by the infarcted vessel. Both of
these approaches focus on the acute mechanism of MI and attempt to restore
adequate coronary blood flow.
Previous studies have reported lower mortality rates for patients with acute MI
and CS who subsequently undergo either PCI or CABG procedures compared with
rates for patients treated with conventional therapy alone (no revascularization).2-8
Furthermore, survival seems to be contingent on the success of restoration of blood
flow within the infarcted vessel.3,6,7,9 Short-term survival for these cohorts of
patients ranges from 47% to 65%. These results, although satisfactory compared
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grim. We have considered whether such revascularization
strategies alone might be insufficient to reverse the clinical
condition of shock in these patients and whether a greater
level of cardiac and circulatory support is necessary.
The use of left ventricular assist devices (LVADs) for the
treatment of end-stage heart failure is well established, both
in terms of bridging patients to cardiac transplantation and
providing long-term support as a means of destination ther-
apy.10 Less clearly defined is the role of LVADs in the
setting of acute MI complicated by CS. Early reports show
modest success with this modality of support, and patients
are either weaned from LVADs or effectively bridged to
cardiac transplantation.11-15 With improving clinical out-
comes of LVADs, their role as primary therapy for acute MI
complicated by CS needs to be evaluated.
Methods
This study protocol was approved by the respective institutional
review boards of Columbia University, the College of Physicians
and Surgeons (New York, NY), and Brigham & Women’s Hospi-
tal (Boston, Mass). Data were retrospectively analyzed after data-
bases were stripped of all patient identifiers and a unique code
number was used for each study subject.
Acute MI was defined as that having occurred 3 months or less
before LVAD implantation and was manifest by ST-segment ele-
vation of greater than 1 mm on electrocardiography, increased
cardiac enzyme levels (creatine kinase MB fraction, troponin,
lactic dehydrogenase, and myoglobin), and written documentation
of diagnosis by an attending cardiologist. The broad definition of
acute MI was established to ensure thorough inclusion and char-
acterization of all patients who received LVADs as a direct result
of acute MI and CS. This time interval also accommodated for the
additional time that might have elapsed for patients who first
underwent revascularization. CS was confirmed by both clinical
and hemodynamic criteria and was required to be a direct result of
the acute MI. Clinical criteria included systolic blood pressure of
less than 90 mm Hg or the need for intravenous vasopressors to
maintain a systolic blood pressure of 90 mm Hg or greater, as well
as evidence of end-organ hypoperfusion, such as diminished uri-
nary output (30 mL/h) or cool extremities. Hemodynamic crite-
ria included a documented cardiac index of less than 2.2
L · min1 · m2 and pulmonary artery diastolic pressure or pul-
monary capillary wedge pressure of 15 mm Hg or greater.
Of all the patients who received LVADs at the 2 institutions
from October 1991 through December 2003, 74 were identified
who had acute anterior wall MI and CS as their primary indication.
All patients with diagnoses of chronic congestive heart failure and
nonanterior wall MIs were excluded to eliminate alternate possible
indications for LVAD support. Six patients received ABIOMED
(ABIOMED, Inc, Danvers, Mass) BVS 5000 biventricular support
systems, 5 received ABIOMED BVS 5000 LVADs, 1 received a
Thoratec (Thoratec Corp, Pleasanton, Calif) paracorporeal LVAD,
9 received HeartMate (Thoratec Corp) implantable pneumatic
LVADs, and the remaining 53 received HeartMate vented-electric
LVADs. Twenty-eight patients underwent direct LVAD implanta-
tion after acute anterior wall MI and CS (LVAD), and 46 under-
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tually requiring LVAD support (CABG plus LVAD).
The 2 groups were compared in regard to patient demographics,
time interval between diagnosis of acute MI and LVAD insertion
(in days), and preoperative intra-aortic balloon pump use. Out-
come variables included bridge-to-transplantation rate, LVAD ex-
plantation rate, 6- and 12-month survivals after LVAD placement
(combined bridge to transplantation, LVAD explantation, and on-
going LVAD support rates), early mortality (30 day) rate, overall
mortality, total hospital length of stay (LOS), intensive care unit
(ICU) LOS, and posttransplantation survival.
A second comparison was made between those patients receiv-
ing LVADs for 7 days or less (acute) and 7 days or more (sub-
acute) after acute MI and CS, irrespective of revascularization
status. Similar preoperative and clinical outcome variables were
analyzed.
Data were represented as frequency distributions and simple
percentages. Values of continuous variables were expressed as
means  standard deviation. Continuous variables were com-
pared by independent samples t tests, and categorical variables
were compared by 2 and Fisher exact tests, where appropriate.
Kaplan-Meier analysis was used to calculate long-term survival
with a log-rank P value when comparing groups. Actuarial
survival was calculated by constructing life tables. All data




The clinical characteristics of patients with LVADs accord-
ing to group (LVAD vs CABG plus LVAD and acute versus
subacute) are outlined in Table 1. The overall mean age was
53.6  8.8 years. Fifty-eight (78.4%) patients were male,
and 16 (21.6%) were female. Mean and median acute MI-
LVAD intervals were 9.7  13.6 days and 5.0 days, respec-
tively, for the entire study cohort but were otherwise equiv-
alent between the LVAD and CABG plus LVAD groups. In
the CABG plus LVAD group, the mean time interval be-
tween diagnosis of acute MI and CABG was 5.1 7.8 days,
and the mean time interval between CABG and LVAD
implantation was 3.8  8.0 days. Three patients were still
receiving LVAD support at the time of data analysis (1 in
the LVAD group and 2 in the CABG plus LVAD group)
and were therefore censored from calculation of transplan-
tation and explantation rates.
Bridge-to-Transplantation Success and LVAD
Explantation
The bridge-to-transplantation success rate was significantly
higher in the LVAD group compared with that in the CABG
plus LVAD group (P  .041, Figure 1). LVAD explantation
rates were similar between the LVAD and CABG plus
LVAD groups and between the acute and subacute MI-
LVAD interval groups (Figures 1 and 2). The overall suc-
cess rate to either transplantation or explantation was sig-
nificantly higher in the acute MI-LVAD interval group
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Pcompared with that in the subacute MI-LVAD interval
group (P  .013, Figure 2).
Post-LVAD Survival
In absolute percentages the 6- and 12-month post-LVAD
survivals for the entire study cohort were 67.6% and 63.5%,
respectively. When these rates were evaluated according to
revascularization status, both 6- and 12-month post-LVAD
survivals were significantly higher in the LVAD group than
in the CABG plus LVAD group (P  .006, Figure 3).
Postoperative Mortality
Early (30 day) mortality was significantly higher in the
CABG plus LVAD group compared with that in the LVAD
group (18 [39.1%] patients vs 4 [14.3%] patients, P .020)
TABLE 1. Clinical characteristics of patients receiving LV
LVAD CABG plus LVAD
Age (y) 55.6  9.4 52.4  8.3
Sex
Male 20 (71.4%) 38 (82.6%)
Female 8 (28.6%) 8 (17.4%)
Race
White 26 (92.8%) 37 (82.2%)
African American 1 (3.6%) 2 (4.4%)
Other 1 (3.6%) 6 (13.3%)
Diagnosis
CAD 26 (92.9%) 43 (93.5%)
ICM 2 (7.1%) 3 (6.50%)
Other 0 (0.0%) 0 (0.0%)
IABP use 25 (89.3%) 38 (82.6%)
MI-LVAD interval (d) 11.1  16.8 8.8  11.3
LVAD, Left ventricular assist device; CABG, coronary artery bypass gra
intra-aortic balloon pump; MI, myocardial infarction.
Figure 1. Clinical outcomes of patients receiving LVADs: LVAD
versus CABG plus LVAD groups.
The Journal of Thoraciand in the acute compared with the subacute MI-LVAD
interval groups (18 [38.3%] patients vs 4 [14.8%] patients,
P  .033).
Overall mortality (early and late) was equivalent be-
tween the LVAD and CABG plus LVAD groups (P 
.106, Figure 1) but significantly higher in the acute versus
subacute MI-LVAD interval group (P  .013, Figure 2).
Duration of LVAD Support
The mean duration of LVAD support for all patients was
75.4  91.3 days. The mean duration of LVAD support up
to transplantation, device explantation, or death was 92.5 
89.0 days (range, 16-407 days), 62.4  98.0 days (range,
4-83 days), and 56.7  102.3 days (range, 0-385 days),
respectively.
P value Acute Subacute P value
.129 51.5  9.4 57.4  6.0 .005
.257 36 (76.6%) 22 (81.5%) .623
11 (23.4%) 5 (18.5%)
.199 39 (84.8%) 24 (88.9%) .622
.855 2 (4.3%) 1 (3.7%) .894
.168 5 (10.9%) 2 (7.4%) .628
.918 45 (95.7%) 24 (88.9%) .258
.918 2 (4.3%) 3 (11.1%) .258
1.000 0 (0.0%) 0 (0.0%) 1.000
.434 42 (89.4%) 21 (77.8%) .178
.490 3.0  2.3 21.3  17.1 .001
CAD, coronary artery disease; ICM, idiopathic cardiomyopathy; IABP,
Figure 2. Clinical outcomes of patients receiving LVADs: acuteADs
fting;versus subacute MI-LVAD interval groups.
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Total hospital LOS was 60.0  56.2 days in the LVAD
group and 39.9 34.8 days in the CABG plus LVAD group
(P  .353). Total hospital LOS was significantly greater in
the subacute MI-LVAD interval group than in the acute
MI-LVAD interval group (59.1 55.9 vs 34.5 32.8 days,
P  .022). ICU LOS was similar between the LVAD and
CABG plus LVAD groups (14.2 9.8 vs 17.6 14.5 days,
P  .480) and between the acute and subacute MI-LVAD
interval groups (17.4 21.7 vs 13.9 9.0 days, P .473).
Posttransplantation Survival
Posttransplantation actuarial survivals at 1, 3, 5, and 7 years
in the LVAD and CABG plus LVAD groups were 94.7%,
94.7%, 94.7%, and 94.7% and 79.5%, 74.2%, 67.1%, and
67.1% (P  .066), respectively. Survivals in the acute and
subacute MI-LVAD interval groups were 85.4%, 80.0%,
80.0%, and 80.0% and 88.9%, 88.9%, 80.0%, and 80.0% (P
 .764), respectively.
Discussion
Acute MI complicated by CS remains a highly morbid
disease entity. The SHOCK (SHould we emergently revas-
cularize Occluded Coronaries for cardiogenic shocK?) trial
is the only randomized controlled clinical study that has
evaluated the efficacy of revascularization (through PCI or
CABG) versus conventional medical therapy in the treat-
ment of CS complicating acute MI.2 Although emergency
revascularization did not significantly reduce 30-day mor-
tality, after 6 months, there was a significant survival benefit
with revascularization compared with medical therapy, an
advantage that extended to 1 year. Nonetheless, these sur-
vivals were mediocre, at best 49.7% at 6 months and 46.7%
Figure 3. Post-LVAD survivals in the LVAD and CABG plus LVAD
groups.at 1 year.
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which sought to determine whether LVAD insertion might
be considered as primary therapy for acute MI and CS in
lieu of revascularization. Numerous design modifications
and adjustments in perioperative management have been
applied to LVADs as a result of past clinical experience,
such that bridge-to-transplantation success rates of 60% to
73% are now commonly reported.16-19 Such improvements
in survival with the judicious application of LVADs might
similarly translate to the acute MI and CS population.
In this study, patients who had acute anterior wall MI
complicated by CS and subsequently underwent direct
LVAD implantation had significantly higher 6- and 12-
month post-LVAD survivals than those who underwent
attempted revascularization with CABG before eventually
requiring LVAD support. These findings are curious in light
of observations by other studies that patients referred for
revascularization, either PCI or CABG, are generally
younger and healthier.20-22 They suggest that despite the
fact that select patients with acute MI and CS might be
clinically stable enough to undergo revascularization by
way of CABG, when these patients ultimately require
LVAD support, the additional CABG intervention might
confer heightened post-LVAD mortality.
The overall 6- and 12-month post-LVAD survivals for
the entire LVAD population in this study were 67.6% and
63.5%, respectively. For the CABG plus LVAD group,
these rates were 54.4% and 52.2%, respectively. Therefore,
even the more ill-fated of the 2 LVAD cohorts, and certainly
the LVAD population as a whole, achieved higher survivals
than did the early revascularization group in the SHOCK
trial (49.7% and 46.7%, respectively). Although this com-
parison pits the results of an observational study against
those of a prospective, randomized clinical trial, the differ-
ences in survival are compelling. These findings suggest
that the application of LVAD support at any point in the
treatment course for acute MI and CS improves survival,
regardless of any attempts toward revascularization. The
exclusion of revascularization through CABG would seem
to heighten survival even further.
The higher early mortality rate in the acute versus sub-
acute MI-LVAD interval group portrays the fact that the
acute group represents a sicker cohort of patients. Indeed, it
is likely the severity of CS in these patients that prompts
immediate LVAD implantation. The greater incidence of
early mortality within this group probably represents indi-
viduals dying of their illness compounded by surgical in-
tervention rather than the development of complications
related to surgical intervention alone.
Posttransplantation survivals between the LVAD and
CABG plus LVAD groups and between the acute and
subacute MI-LVAD interval groups were equivalent. How-
ever, the trend toward lower posttransplantation survival in
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Pthe CABG plus LVAD group intimates that the post-LVAD
systemic milieu in this group might be persistently compro-
mised in such a way that carries into the posttransplantation
state.
Although this study suggests that CABG alone confers
poorer survival than LVAD as primary therapy for acute MI
and CS, the question might arise whether patients might fare
best with simultaneous CABG and LVAD. The LVAD can
facilitate unloading of the heart in the critical perioperative
phase to minimize the work performed by the myocardium.
Conversely, the utility of CABG and its associated pro-
longed operative and cardiopulmonary bypass times is de-
batable because most of these patients undergo transplanta-
tion anyway.
Limitations of the Study
The limitations of this study are those inherent with retro-
spective analyses. Selection bias is evident because this
study fails to account for the probable vast number of
patients in similar clinical scenarios who undergo revascu-
larization and require no further intervention. Therefore, the
patients in the CABG plus LVAD group likely represent a
particularly sick cohort of individuals whose shock was not
ameliorated by revascularization alone. Data on the propor-
tion of these patients who presented with failed grafts are
lacking.
The definition of acute MI as having occurred 3
months or less before LVAD insertion was established to
ensure thorough inclusion of all qualified patients for this
study. This broad inclusion interval likely introduces 2
distinct entities of patients with acute MI and CS who
might arguably be managed differently. However, it is
often difficult to predict and discern truly sick patients
from those slightly less sick on the basis of acute MI-
LVAD interval alone, and we did not want to exclude
from our analysis those requiring later LVAD insertion.
Revascularization by way of PCI is not represented in
this study when, in fact, the majority of revascularization
efforts are carried out with this approach. CABG often
becomes an option only after PCI has failed or is not
feasible, again emphasizing the relative sickness of this
group of patients. Unfortunately, data reporting the fre-
quency of failed PCI attempts referred for CABG are not
available in this study.
Conclusions
Patients with acute anterior wall MI complicated by CS
who undergo revascularization through CABG only to
subsequently require LVAD support have lower post-
LVAD survivals than those in a similar clinical setting
who undergo direct LVAD implantation. The decision-
making processes that underlie patient selection and de-
termination of therapeutic intervention need to be eluci-
The Journal of Thoracidated. Ultimately, confirmation of the findings in this
study would require conducting a large, multicenter, ran-
domized clinical trial comparing revascularization (PCI
or CABG) versus LVAD support as primary therapy for
acute MI complicated by CS.
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